A Phase II Prospective Study of Epidermal Growth Factor Receptor (Her-1/EGFR) Inhibitor-Induced Dermatologic Toxicity: Validation of the Functional Assessment of Cancer Therapy � EGFRI 18 (FACT-EGFRI 18) Questionnaire for EGFRI-induced Skin Toxicities

Colorectal or lung cancer patients planning to receive one of the following HER1/EGFR inhibitor therapies for at least 6 weeks: cetuximab 400mg/m2 loading dose and 250mg/m2 weekly, cetuximab 500mg/m2 every 2 weeks, Panitumumab 6mg/kg every 2 weeks, or erlotinib 100-150mg daily; prior HER1/EGFR inhibitor therapy allowed if all skin toxicities are resolved; no serious concomitant skin disorders (atopic dermatitis, contact dermatitis, psoriasis, rosacea, severe photosensitivity, scleroderma, steroid-induced acne, xerosis); must not receive concomitant medications that can cause skin rash or other dermatologic reactions; Zubrod PS of 0-2; able to complete questionnaires in English; not planning to receive concurrent external bean radiation therapy; concurrent participation in other therapeutic clinical trials is allowed; able to complete baseline S1013 FACT-EGFRI 18 within 3 days prior to initiations of EGFRI therapy.